# OnCo record paper-napoli-3-lancet-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-napoli-3-lancet-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-napoli-3-lancet-2023" ;
  schema:name "NAPOLI-3: NALIRIFOX versus gemcitabine plus nab-paclitaxel as first treatment for metastatic pancreatic cancer"@en ;
  schema:description "NAPOLI-3 randomised 770 patients with untreated metastatic pancreatic cancer to NALIRIFOX, a four-drug regimen built on liposomal irinotecan, or to gemcitabine plus nab-paclitaxel, the doublet most patients receive. NALIRIFOX lengthened life and delayed progression, the first positive first-line trial in a decade, though conventional FOLFIRINOX remains the usual choice where affordable."@en ;
  schema:url <https://onco.cc/key-papers/paper-napoli-3-lancet-2023/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=NAPOLI-3+NALIRIFOX+Wainberg+Lancet>, <https://clinicaltrials.gov/study/NCT04083235> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(23)01366-1> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Wainberg ZA, Melisi D, Macarulla T, et al." ;
  onco:cancers <https://onco.cc/cancers/pancreatic/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/topoisomerase-inhibitors/>, <https://onco.cc/technologies/platinum/> ;
  onco:companies <https://onco.cc/companies/servier/> ;
  onco:terms <https://onco.cc/terms/os/>, <https://onco.cc/terms/pfs/>, <https://onco.cc/terms/first-line/>, <https://onco.cc/terms/standard-of-care/> ;
  onco:people <https://onco.cc/people/tanios-bekaii-saab/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-undruggable-targets/>, <https://onco.cc/bottlenecks/b-drug-pricing/>, <https://onco.cc/bottlenecks/b-tme-immunosuppression/> ;
  onco:journals <https://onco.cc/journals/lancet/> .